Teladoc’s Mixed Performance: Strong IC Growth Overshadowed by BH Segment Uncertainty Leading to Hold Rating

Analyst Charles Rhyee from TD Cowen maintained a Hold rating on Teladoc and keeping the price target at $8.00.

Charles Rhyee has given his Hold rating due to a combination of factors surrounding Teladoc’s recent performance and future prospects. The company reported strong revenue and EBITDA figures that exceeded consensus expectations, particularly in the Integrated Care (IC) segment, which showed promising international growth and increased guidance. However, concerns arise from the Behavioral Health (BH) segment, where higher churn rates and a reduced EBITDA guidance suggest a potential decline in year-over-year growth.
Management’s emphasis on the time needed for the transition of BH to a payor model adds uncertainty about the segment’s return to growth by 2026. While the IC segment’s performance was solid, the uncertainty in the BH segment, particularly regarding its future growth trajectory, leads to a neutral outlook. This combination of positive and negative factors results in a Hold rating, as the potential for growth is counterbalanced by the risks associated with the BH segment’s transition and performance.